miRNA‑885‑3p inhibits docetaxel chemoresistance in lung adenocarcinoma by downregulating Aurora A

Cao,Jiongrui; Geng,Jian; Chu,Xiaoyuan; Wang,Rui; Huang,Guichun; Chen,Longbang

doi:10.3892/or.2018.6858

miRNA‑885‑3p inhibits docetaxel chemoresistance in lung adenocarcinoma by downregulating Aurora A

Authors:
- Jiongrui Cao
- Jian Geng
- Xiaoyuan Chu
- Rui Wang
- Guichun Huang
- Longbang Chen
View Affiliations

Affiliations: Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, P.R. China
Published online on: November 9, 2018 https://doi.org/10.3892/or.2018.6858
Pages: 1218-1230

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aurora A is a member of the mitotic serine/threonine kinase family. It is involved in key processes during mitosis and meiosis, and Aurora A upregulation is implicated in malignant transformation. In the present study, we revealed that Aurora A expression was significantly higher in docetaxel‑resistant lung adenocarcinoma (LAD) cells than in parental cells. Higher levels of Aurora A expression were significantly correlated with higher chemoresistance and proliferation in LAD cells, while silencing Aurora A promoted caspase‑3‑dependent cell apoptosis by downregulating NF‑κB and Bcl‑2 and upregulating Bax expression. In addition, an increased proportion of cells in the G2/M phase and a decreased proportion of cells in the S phase were observed due to the suppression of Aurora A. Furthermore, we identified that microRNA‑885‑3p (miR‑885‑3p) could target Aurora A directly. There was significantly lower miR‑885‑3p expression in docetaxel‑resistant LAD cells than in parental LAD cells. miR‑885‑3p could modulate the docetaxel response, cell proliferation and apoptosis in LAD cells in vitro. Moreover, we found that Aurora A overexpression or miR‑885‑3p inhibition was associated with more aggressive behaviour in LAD cells. Thus, miR‑885‑3p/Aurora A may be involved in the chemoresistance of LAD cells, and assessing miR‑885‑3p/Aurora A expression may be a potential method for indicating chemosensitivity to docetaxel‑based chemotherapy.

View Figures

View References

1	Tunali I, Stringfield O, Guvenis A, Wang H, Liu Y, Balagurunathan Y, Lambin P, Gillies RJ and Schabath MB: Radial gradient and radial deviation radiomic features from pre-surgical CT scans are associated with survival among lung adenocarcinoma patients. Oncotarget. 8:96013–96026. 2017. View Article : Google Scholar : PubMed/NCBI
2	Domagala-Kulawik J and Raniszewska A: How to evaluate the immune status of lung cancer patients before immunotherapy. Breathe. 13:291–296. 2017. View Article : Google Scholar : PubMed/NCBI
3	Xu-Welliver M and Carbone DP: Blood-based biomarkers in lung cancer: Prognosis and treatment decisions. Transl Lung Cancer Res. 6:708–712. 2017. View Article : Google Scholar : PubMed/NCBI
4	Torigoe H, Soh J, Tomida S, Namba K, Sato H, Katsui K, Hotta K, Shien K, Yamamoto H, Yamane M, et al: Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer. J Thorac Dis. 9:3076–3086. 2017. View Article : Google Scholar : PubMed/NCBI
5	Kim ST, Kyung EJ, Suh JS, Lee HS, Lee JH, Chae SI, Park ES, Chung YH, Bae J, Lee TJ, et al: Phosphatidylcholine attenuated docetaxel-induced peripheral neurotoxicity in rats. Drug Chem Toxicol. 41:476–485. 2018. View Article : Google Scholar : PubMed/NCBI
6	Matsunaga T, Saito H, Endo S, Iguchi K, Soda M, El-Kabbani O, Hara A and Ikari A: Roles of aldo-keto reductases 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance. Free Radic Res. 50:1296–1308. 2016. View Article : Google Scholar : PubMed/NCBI
7	Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry D: Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
8	Zhang K, Chen J, Chen D, Huang J, Feng B, Han S, Chen Y, Song H, De W, Zhu Z, et al: Aurora A promotes chemoresistance in hepatocelluar carcinoma by targeting NF-kappaB/microRNA-21/PTEN signaling pathway. Oncotarget. 5:12916–12935. 2014.PubMed/NCBI
9	Lykkesfeldt AE, Iversen BR, Jensen MB, Ejlertsen B, Giobbie-Hurder A, Reiter BE, Kirkegaard T and Rasmussen BB: Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. Acta Oncol. 57:67–73. 2018. View Article : Google Scholar : PubMed/NCBI
10	Lee DH, Kim CG, Lim Y and Shin SY: Aurora kinase A inhibitor TCS7010 demonstrates pro-apoptotic effect through the unfolded protein response pathway in HCT116 colon cancer cells. Oncol Lett. 14:6571–6577. 2017.PubMed/NCBI
11	Tagal V, Wei S, Zhang W, Brekken RA, Posner BA, Peyton M, Girard L, Hwang T, Wheeler DA, Minna JD, et al: SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 8:140982017. View Article : Google Scholar : PubMed/NCBI
12	Rui W, Bing F, Hai-Zhu S, Wei D and Long-Bang C: Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med. 14:206–214. 2010. View Article : Google Scholar : PubMed/NCBI
13	Xiao F, Qiu H, Cui H, Ni X, Li J, Liao W, Lu L and Ding K: MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling. Oncogene. 34:1968–1978. 2015. View Article : Google Scholar : PubMed/NCBI
14	Summerer I, Niyazi M, Unger K, Pitea A, Zangen V, Hess J, Atkinson MJ, Belka C, Moertl S and Zitzelsberger H: Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiat Oncol. 8:2962013. View Article : Google Scholar : PubMed/NCBI
15	Bury L, Coelho PA, Simeone A, Ferries S, Eyers CE, Eyers PA, Zernicka-Goetz M and Glover DM: Plk4 and Aurora A cooperate in the initiation of acentriolar spindle assembly in mammalian oocytes. J Cell Boil. 216:3571–3590. 2017. View Article : Google Scholar
16	Martin D, Fallaha S, Proctor M, Stevenson A, Perrin L, McMillan N and Gabrielli B: Inhibition of Aurora A and Aurora B is required for the sensitivity of HPV-Driven cervical cancers to Aurora kinase inhibitors. Mol Cancer Ther. 16:1934–1941. 2017. View Article : Google Scholar : PubMed/NCBI
17	Simpson PV, Casari I, Paternoster S, Skelton BW, Falasca M and Massi M: Defining the anti-cancer activity of tricarbonyl rhenium complexes: Induction of G2/M cell cycle arrest and blockade of Aurora A kinase phosphorylation. Chemistry. 23:6518–6521. 2017. View Article : Google Scholar : PubMed/NCBI
18	Asteriti IA, De Mattia F and Guarguaglini G: Cross-talk between AURKA and Plk1 in mitotic entry and spindle assembly. Front Oncol. 5:2832015. View Article : Google Scholar : PubMed/NCBI
19	Vo TT, Park JH, Seo JH, Lee EJ, Choi H, Bae SJ, Le H, An S, Lee HS, Wee HJ, et al: ARD1-mediated aurora kinase A acetylation promotes cell proliferation and migration. Oncotarget. 8:57216–57230. 2017. View Article : Google Scholar : PubMed/NCBI
20	Alcaraz-Sanabria A, Nieto-Jimenez C, Corrales-Sanchez V, Serrano-Oviedo L, Andrés-Pretel F, Montero JC, Burgos M, Llopis J, Galán-Moya EM, Pandiella A, et al: Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer. Mol Cancer Ther. 16:2552–2562. 2017. View Article : Google Scholar : PubMed/NCBI
21	Qiao W, Guo B, Zhou H, Xu W, Chen Y, Liang Y and Dong B: miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA. Biochem Biophys Res Commun. 486:43–48. 2017. View Article : Google Scholar : PubMed/NCBI
22	Mesic A, Markocic E, Rogar M, Juvan R, Hudler P and Komel R: Single nucleotide polymorphisms rs911160 in AURKA and rs2289590 in AURKB mitotic checkpoint genes contribute to gastric cancer susceptibility. Environ Mol Mutagen. 58:701–711. 2017. View Article : Google Scholar : PubMed/NCBI
23	Lu Y, Liu Y, Jiang J, Xi Z, Zhong N, Shi S, Wang J and Wei X: Knocking down the expression of Aurora A gene inhibits cell proliferation and induces G2/M phase arrest in human small cell lung cancer cells. Oncol Rep. 32:243–249. 2014. View Article : Google Scholar : PubMed/NCBI
24	Kozyreva VK, Kiseleva AA, Ice RJ, Jones BC, Loskutov YV, Matalkah F, Smolkin MB, Marinak K, Livengood RH, Salkeni MA, et al: Combination of eribulin and Aurora A inhibitor MLN8237 prevents metastatic colonization and induces cytotoxic autophagy in breast cancer. Mol Cancer Ther. 15:1809–1822. 2016. View Article : Google Scholar : PubMed/NCBI
25	Maimaiti Y, Jie T, Jing Z, Changwen W, Pan Y, Chen C and Tao H: Aurora kinase A induces papillary thyroid cancer lymph node metastasis by promoting cofilin-1 activity. Biochem Biophys Res Commun. 473:212–218. 2016. View Article : Google Scholar : PubMed/NCBI
26	Sun JM, Yang LN, Xu H, Chang B, Wang HY and Yang G: Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells. Am J Cancer Res. 5:1133–1145. 2015.PubMed/NCBI
27	De Bacco F, D'Ambrosio A, Casanova E, Orzan F, Neggia R, Albano R, Verginelli F, Cominelli M, Poliani PL, Luraghi P, et al: MET inhibition overcomes radiation resistance of glioblastoma stem-like cells. EMBO Mol Med. 8:550–568. 2016. View Article : Google Scholar : PubMed/NCBI
28	Bhat P, Kriel J, Shubha Priya B, Basappa, Shivananju NS and Loos B: Modulating autophagy in cancer therapy: Advancements and challenges for cancer cell death sensitization. Biochem Pharmacol. 147:170–182. 2017. View Article : Google Scholar : PubMed/NCBI
29	Caliskan M, Guler H and Bozok Cetintas V: Current updates on microRNAs as regulators of chemoresistance. Biomed Pharmacother. 95:1000–1012. 2017. View Article : Google Scholar : PubMed/NCBI
30	Bourguignon LY, Earle C and Shiina M: Activation of matrix hyaluronan-mediated CD44 signaling, epigenetic regulation and chemoresistance in head and neck cancer stem cells. Int J Mol Sci. 18:E18492017. View Article : Google Scholar : PubMed/NCBI
31	Huang Y, Chuang AY and Ratovitski EA: Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure. Cell Cycle. 10:3938–3947. 2011. View Article : Google Scholar : PubMed/NCBI
32	Lo UG, Lee CF, Lee MS and Hsieh JT: The role and mechanism of epithelial-to-mesenchymal transition in prostate cancer progression. Int J Mol Sci. 18:E20792017. View Article : Google Scholar : PubMed/NCBI
33	Zheng HC: The molecular mechanisms of chemoresistance in cancers. Oncotarget. 8:59950–59964. 2017.PubMed/NCBI
34	D'Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V, et al: The mitotic kinase Aurora - a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERalpha(+) breast cancer cells. Oncogene. 33:599–610. 2014. View Article : Google Scholar : PubMed/NCBI
35	Cui S, Zhang K, Li C, Chen J, Pan Y, Feng B, Lu L, Zhu Z, Wang R and Chen L: Methylation-associated silencing of microRNA-129-3p promotes epithelial-mesenchymal transition, invasion and metastasis of hepatocelluar cancer by targeting Aurora A. Oncotarget. 7:78009–78028. 2016. View Article : Google Scholar : PubMed/NCBI